Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by topic
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by topic
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are here
Home
Exhaustion
Email alerts
Exhaustion
Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors
Catherine T.
Le
,
William J.
Murphy
Journal for ImmunoTherapy of Cancer
Dec 2019,
7
(1)
291;
DOI:
10.1186/s40425-019-0789-4
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Paola
Dama
,
Marshall
Tang
,
Noreen
Fulton
,
Justin
Kline
,
Hongtao
Liu
Journal for ImmunoTherapy of Cancer
Dec 2019,
7
(1)
175;
DOI:
10.1186/s40425-019-0611-3
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
Andressa S.
Laino
,
B. C.
Betts
,
A.
Veerapathran
,
I.
Dolgalev
,
A.
Sarnaik
,
S. N.
Quayle
,
S. S.
Jones
,
J. S.
Weber
,
David M.
Woods
Journal for ImmunoTherapy of Cancer
Dec 2019,
7
(1)
33;
DOI:
10.1186/s40425-019-0517-0
Combination immunotherapy: Where do we go from here?
Abigail E.
Overacre
,
Sema
Kurtulus
,
Mario
Sznol
,
Drew M.
Pardoll
,
Ana
Anderson
,
Dario A. A.
Vignali
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(1)
38;
DOI:
10.1186/s40425-015-0083-z
Special collections
COVID-19
(21)
Editor's choice
JITC
Basic Tumor Immunology
(261)
Case Reports
(171)
Clinical Trials Monitor
(13)
Clinical/Translational Cancer Immunotherapy
(474)
Commentary/Editorials
(90)
COVID-19 and Cancer Immunotherapy
(4)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(26)
Guidelines and Consensus Statements
(25)
Immune Cell Therapies and Immune Cell Engineering
(47)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(176)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(34)
Reviews
(144)
Open access
(1574)
Press releases